Top Markets
#1 Bedrock Bedrock +50.85%
#2 pippin pippin +21.68%
#3 IQ IQ +20.70%
#4 Naoris Protocol Naoris Protocol +17.39%
#5 Irys Irys +16.18%
#6 Magma Finance Magma Finance +15.58%
#7 ETHGas ETHGas +15.36%
#8 Aria.AI Aria.AI +15.19%
#9 パンチ (Punch) パンチ (Punch) +14.59%
#10 Bitway Bitway +12.30%
Coin of the day
Bedrock Bedrock
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Classifica tra le azioni #20442
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Prezzo delle azioni
$0.16328419
Capitalizzazione di mercato
$204.14K
Variazione (1 giorno)
4.35%
Variazione (1 anno)
102.45%
Paese
GB
Scambia Fusion Antibodies plc (FAB)

Categoria

Healthcare
Ricavi di Fusion Antibodies plc (FAB)
Ricavi nel Sep 2025 TTM: $2.15M
Secondo gli ultimi rapporti finanziari di Fusion Antibodies plc, i ricavi attuali dell'azienda (TTM) sono pari a $2.15M. Nel 2024, l'azienda ha registrato ricavi di $1.43M una diminuzione rispetto a i ricavi dell'anno 2023, che erano pari a $3.58M. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Fusion Antibodies plc da 2013 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
2026 (TTM) $2.15M -15.49%
2025 $2.54M 77.00%
2024 $1.43M -59.95%
2023 $3.58M -43.24%
2022 $6.31M 9.89%
2021 $5.74M 18.80%
2020 $4.83M 70.09%
2019 $2.84M -24.66%
2018 $3.77M 57.07%
2017 $2.40M 12.81%
2016 $2.13M 57.86%
2015 $1.35M 11.90%
2014 $1.20M 95.78%
2013 $615.46K 0.00%
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B 2,257,473.65%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B 560,997.32%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 668,407.67%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 423,215.14%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $5.49B 255,843.08%
NL